All In Biotech

Drug Trial Radar · NCT07794150

A Study to Assess the Skin Irritation and Sensitization of Estradiol/Levonorgestrel TDS in Healthy Postmenopausal Subjects

A Multiple-Center Study to Evaluate the Skin Irritation and Sensitization Potential of a Test Estradiol/Levonorgestrel Transdermal Delivery System (Corium TDS)

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Corium Innovations, Inc.Industry
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The two products used in this study are transdermal patches that contain selegiline. The test drug is the Estradiol/Levonorgestrel Transdermal Delivery System (TDS). The comparator drug is the Climara Pro® TDS. The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products. The comparison will be based on how the skin responds to repeated applications of each TDS. This includes the assessment of skin irritation during the Induction Period and the evaluation of possible allergic or sensitization reactions after the Challenge Period. In addition, the adhesion of each patch (how well the patch sticks to the skin over time) will be regularly checked, as this is important for both product performance and skin safety.

Conditions

  • Menopause
  • Healthy Female Participants

Interventions

  • Estradiol/Levonorgestrel Transdermal SystemDrug

    1/2 Estradiol/Levonorgestrel Delivery System 0.045 mg per day/ 0.015 mg per day and 1/2 Climara Pro® patch 0.045 mg per day/ 0.015 mg per day will be administered simultaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Irritation Score (MIS) for the Test and Reference Patches During the 21-Day Continuous Application PeriodTime frame: From Day 1 through Day 22 (21-day continuous application period; assessments 30 minutes [+10 minutes] after patch removal on Days 8, 15, and 22)
  2. Number of Participants With a Potential Sensitization Response to the Test or Reference PatchTime frame: At the last evaluation more than 24 hours after challenge patch removal (48 or 72 hours); for rechallenged participants, at the last evaluation more than 24 hours after rechallenge patch removal (48 or 72 hours)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Novum Pharmaceutical Research Services

    Las Vegas, Nevada · Recruiting

  • Lambda Therapeutic Research Ltd.

    Ahmedabad, Gujarat, India · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.